Dr. I-Chow Joe Hsu, MD

Dr. Hsu practices at UCSF Helen Diller Medical Center at Parnassus Heights in San Francisco, California, part of University of California Health.

Dr. Hsu's NPI, 1144263039, was assigned on June 14, 2006. Dr. Hsu graduated from The Johns Hopkins University School of Medicine in 1991. Dr. Hsu holds California license A51033.

Dr. Hsu's primary practice is UCSF Helen Diller Medical Center at Parnassus Heights, at 505 Parnassus Ave, Box 0296, San Francisco, CA 94143 in San Francisco County. The practice phone is (415) 353-2733.

Dr. Hsu's primary practice is UCSF Helen Diller Medical Center at Parnassus Heights in San Francisco, California, part of University of California Health. The medical group on file is UCSF Pediatrics. Dmand AI also links Dr. Hsu to 2 more group practices and clinics and 2 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Hsu practices, 3 sites in all. Vendor and product names are available with a free account.

Radiation oncology is Dr. Hsu's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dr. Hsu is board certified in radiation oncology by the American Board of Radiology. Dr. Hsu is licensed in California.

Dmand AI lists cervical cancer radiation, prostate cancer radiation and uterine cancer radiation among the conditions Dr. Hsu treats.

CMS data shows 900 Medicare services from Dr. Hsu across 18 procedure codes in 2024, for 145 Medicare patients. Medicare paid $158,847 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 145 Medicare patients who saw Dr. Hsu in 2024. The largest group is 75 to 84, with 66 patients. 75% of them have cancer, and 75% have high cholesterol. 18% are also on Medicaid. Their average risk score is 1.35, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Hsu's median patient age at 74, with 25% women.

In 2024, Dr. Hsu wrote 60 Medicare Part D claims for 27 patients. 97% of them were for generic drugs. CMS names the drug for 43 of them, across 1 drug with 11 or more claims each, at $561 in total drug cost. In 2023, CMS named 50 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 87 out of 100 for Dr. Hsu for performance year 2024, reported as part of a group. Dr. Hsu accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Hsu as offering telehealth.

Dmand AI links 103 papers to Dr. Hsu, published from 2005 to 2025. 2018 was the busiest year, with 7. The most frequent topics are Brachytherapy, Prostatic Neoplasms and Radiotherapy Dosage. Dr. Hsu has published most often in Brachytherapy. Dr. Hsu's most frequent co-authors are Mack Roach, MD, Albert Jeh-Seng Chang, MD and Lee-May Chen, MD.

Dmand AI links Dr. Hsu to 5 clinical trials. 2 are still active or recruiting. Conditions studied include Prostatic Neoplasms, Prostatic Diseases and Salivary Gland Adenoma, Pleomorphic. Radiation Therapy Oncology Group sponsors the most, 2.

CMS Open Payments shows 12 general payments to Dr. Hsu from 3 drug and device companies from 2016 to 2024. Consulting fees make up the largest share, 80% of the total. Boston Scientific Corporation paid the most, $12,250.

Dmand AI lists 1 award for Dr. Hsu, most recently Regional Top Doctor in 2014.

Dr. Hsu graduated from The Johns Hopkins University School of Medicine in 1991.

Dr. Hsu is in network with 9 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. Medicare plans come from the most carriers, 7. Check the plan with the practice before a visit.